Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
The main goal of the study is to expand cancer preclinical research results on the usefulness
of SSTR2-Antagonist [99mTc]Tc-TECANT1 in clinical practice. Detection of NEN and monitoring
of response to therapy is still challenging due to their cellular heterogeneity. Initial
preclinical studies suggest that NEN imaging with the use of SSTR2-Antagonist may be
advantageous in comparison to the widely used SSTR2-Agonists.
Recently, novel radiopharmaceuticals, based on SSTR2-Antagonists, were shown to provide
superior SSTR2 visualisation than currently used agonists. The need for molecular imaging of
NEN is expected to grow significantly in the near future due to their increasing incidence
and prevalence. Although a persistent trend to shift the molecular imaging of NEN from
conventional SPECT/CT gamma cameras to PET/CT has been observed in the last decade, labelling
the compound with Tc-99m offers significant advantages by its extremely wide availability,
low cost and low radiation exposure to patients. Effective and accessible molecular imaging
methods as an integral part of personalised patient management are needed to optimise
selection and follow-up of available therapeutic modalities. The Tc-99m-labeled
SSTR2-Antagonist [99mTc]Tc-TECANT1 is expected to be an effective, widely available compound
for quantitative assessment of SSTR2 NEN status, allowing a personalised therapeutic
approach.
Phase:
Early Phase 1
Details
Lead Sponsor:
Jagiellonian University
Collaborators:
Medical University Innsbruck NCBJ Polatom: Narodowe Centrum Badań Jądrowych Polatom University Medical Centre Ljubljana University of Ljubljana